自体免疫疾病诊断的全球市场

全球自体免疫疾病诊断市场规模预计将从 2023 年的 148 亿美元成长到 2028 年的 179 亿美元，预测期内复合年增长率为 3.9%。

从技术角度来看，ELISA部门预计将从 2023 年的 47 亿美元成长到 2028 年的 57 亿美元，复合年增长率为 4.0%。此外，间接萤光(IIF)部门预计将从 2023 年的 39 亿美元增至 2028 年的 47 亿美元，复合年增长率为 3.9%。

本报告调查了全球自体自体免疫疾病诊断市场，并提供了市场和诊断技术的概述、相关法律、市场影响因素和市场机会分析、市场规模趋势和预测，以及各个细分市场和地区的详细信息。我们总结分析、技术/专利趋势、管道分析、ESG动态、竞争形势、主要企业简介等。

目录

第一章简介

第 2 章摘要/亮点

• 市场展望
• 市场摘要

第三章市场概述与定义

• 概述：自体免疫疾病的诊断
• 酵素结合免疫吸附测定法 (ELISA)
• 间接萤光(IIF)
• 多重免疫测量
• 蛋白质印迹（免疫印迹）
• 其他技术
• 适应症
• 类风湿性关节炎
• 全身性红斑性狼疮（SLE）
• 干癣性关节炎
• 多发性硬化症
• 发炎性肠道疾病
• 自体自体免疫疾病诊断的全球法律规范
• 测试检验
• FDA 许可或核准
• 良好生产规范 (GMP)
• 标籤和说明
• 上市后监督
• 品管和品质保证
• 临床效用与医疗指南
• 隐私和资料安全
• 监管场景
• 北美法规
• 拉丁美洲法规
• 亚太地区法规

第四章市场动态

• 市场动态
• 市场驱动因素
• 市场抑制因素
• 市场机会

第五章市场区隔：依地区

• 市场概览/讨论
• 北美洲
• 墨西哥
• 加拿大
• 欧洲
• 德国
• 英国
• 法国
• 义大利
• 西班牙
• 欧洲其他地区
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲/纽西兰
• 亚太地区其他地区
• 其他地区

第六章市场细分：性别

• 市场概览/讨论
• 男性
• 女士
• 北美市场
• 欧洲市场
• 亚太市场
• 其他区域市场

第七章市场细分：按迹象

• 市场概览/讨论
• 1型糖尿病
• 类风湿性关节炎
• 全身性红斑性狼疮（SLE）
• 干癣/干癣性关节炎
• 多发性硬化症
• 发炎性肠道疾病
• 其他的

第八章市场细分：依技术分类

• 酵素免疫分析法测定法 (ELISA)
• 区域市场
• 间接萤光(IIF)
• 区域市场
• 免疫印迹
• 区域市场
• 多重免疫测量
• 区域市场
• 其他的
• 区域市场

第九章 ESG发展

• 环境
• 研究实践
• 供应链永续性
• 废弃物管理
• 能源效率
• 社会方面
• 获得医疗保健
• 患者健康
• 社区参与
• 管治
• 道德商业行为
• 遵守法规
• 董事会多元化
• 透明度和课责
• 案例研究
• Roche
• 罗氏的永续性
• BCC的结语

第10章新趋势和新技术

第十一章竞争形势

• 概述
• 产业场景
• 企业市场占有率

第十二章 专利分析

第13章管道分析

• 临床试验

第十四章 併购与资金筹措

第十五章 公司简介

• ABBOTT
• BD BIOSCIENCES
• BECKMAN COULTER INC.
• BIOMERIEUX
• BIO-RAD (ABD SEROTEC)
• F. HOFFMANN-LA ROCHE AG
• QUEST DIAGNOSTICS INC.
• SIEMENS HEALTHCARE
• THERMO FISHER SCIENTIFIC INC.

第 16 章附录：缩写

Highlights:

The global market for autoimmune disease diagnostics is estimated to increase from $14.8 billion in 2023 to reach $17.9 billion by 2028, at a compound annual growth rate (CAGR) of 3.9% from 2023 through 2028.

The global market for autoimmune disease diagnostics for ELISA segment is estimated to increase from $4.7 billion in 2023 to reach $5.7 billion by 2028, at a compound annual growth rate (CAGR) of 4.0% from 2023 through 2028.

The global market for autoimmune disease diagnostics for Indirect immunofluorescence (IIF) segment is estimated to increase from $3.9 billion in 2023 to reach $4.7 billion by 2028, at a compound annual growth rate (CAGR) of 3.9% from 2023 through 2028.

Report Scope:

This report aims to study the autoimmune disease diagnostics global market size comprehensively. Current and historical market revenues can be estimated based on the technology, by indication, gender and region.

Report Includes:

• 41 data tables and 30 additional tables
• An overview of the global market landscape related to the autoimmune disease diagnostics
• In-depth analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, as well as forecasts for 2028. This analysis includes projections of Compound Annual Growth Rates (CAGRs) spanning through 2028
• Evaluation of the current market size and revenue growth prospects specific to autoimmune disease diagnostics, accompanied by a comprehensive market share analysis categorized by technology, indication, gender, and geographical region
• Detailed description of autoimmune disorder & therapies, and causes such as intrinsic factors, environmental factors, and lifestyle factors, and insights into new diagnostic pathway for autoimmune and inflammatory disorders
• Discussion on role of bioinformatics and biomarkers on autoimmune disorder therapies and information on standardization of test results
• Coverage of new product launches in the therapeutics for autoimmune diseases and performance methods in the detection of autoimmune antibodies
• Coverage of emerging technologies in autoimmune disease diagnostics, recent developments, future opportunities, patent review, and ESG trends
• Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
• Detailed profiles of leading market participants, including Abbott, Beckman Coulter Inc., BioMerieux, Siemens Healthcare, F. Hoffmann-La Roche AG, and Thermo Fisher Scientific

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• What's New in This Update?
• Scope of Report
• Methodology
• Information Sources
• Secondary Research
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview and Definitions

• Overview: Autoimmune Disease Diagnostics
• Enzyme-|Linked Immunosorbent Assay (ELISA)
• Indirect Immunofluorescence (IIF)
• Multiplex Immunoassays
• Western Blot (Immunoblot)
• Other Technologies
• Indications
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus (SLE)
• Psoriatic Arthritis
• Multiple Sclerosis
• Inflammatory Bowel Disease
• The Global Regulatory Structure for Autoimmune Disease Diagnostics
• Test Validation
• FDA Clearance or Approval
• Good Manufacturing Practices (GMP)
• Labeling and Instructions
• Post-Market Surveillance
• Quality Control and Quality Assurance
• Clinical Utility and Medical Guidelines
• Privacy and Data Security
• Regulatory Scenario
• North American Regulations
• Latin American Regulations
• Asia-Pacific Regulations

Chapter 4 Market Dynamics

• Market Dynamics
• Market Drivers
• Market Restraints
• Market Opportunities

Chapter 5 Market Breakdown by Region

• Market Overview and Discussion
• North America
• Mexico
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• Australia and New Zealand
• Rest of Asia-Pacific
• Rest of the World

Chapter 6 Market Breakdown by Gender

• Market Overview and Discussion
• Male
• Female
• North American Market by Gender
• European Market by Gender
• Asia-Pacific Market by Gender
• Rest of the World Market by Gender

Chapter 7 Market Breakdown by Indication

• Market Overview and Discussion
• Type 1 Diabetes
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus (SLE)
• Psoriasis/Psoriatic Arthritis
• Multiple Sclerosis
• Inflammatory Bowel Disease
• Other Indications

Chapter 8 Market Breakdown by Technology

• Enzyme-Linked Immunosorbent Assay (ELISA)
• Regional Markets
• Indirect Immunofluorescence (IIF)
• Regional Markets
• Immunoblot
• Regional Markets
• Multiplex Immunoassays
• Regional Markets
• Others
• Regional Markets

Chapter 9 ESG Development

• Introduction
• Environment
• Research Practices
• Supply Chain Sustainability
• Waste Management
• Energy Efficiency
• Social
• Access to Healthcare
• Patient Well-Being
• Community Engagement
• Governance
• Ethical Business Practices
• Compliance with Regulations
• Board Diversity
• Transparency and Accountability
• Case Study
• Roche
• Sustainability at Roche
• Concluding Remarks from BCC Research

Chapter 10 Emerging Trends and Technologies

• Introduction

Chapter 11 Competitive Landscape

• Overview
• Industry Scenario
• Company Shares

Chapter 12 Patent Analysis

• Patent Analysis by Manufacturer

Chapter 13 Pipeline Analysis

• Clinical Trials

Chapter 14 M&A and Venture Funding Outlook

• Introduction

Chapter 15 Company Profiles

• ABBOTT
• BD BIOSCIENCES
• BECKMAN COULTER INC.
• BIOMERIEUX
• BIO-RAD (ABD SEROTEC)
• F. HOFFMANN-LA ROCHE AG
• QUEST DIAGNOSTICS INC.
• SIEMENS HEALTHCARE
• THERMO FISHER SCIENTIFIC INC.

Chapter 16 Appendix: Acronyms

List of Tables

• Summary Table : Global Market for Autoimmune Disease Diagnostics, by Technology, Through 2028
• Table 1 : Components of ELISA
• Table 2 : Process of ELISA
• Table 3 : Components of Immunofluorescence (IIF)
• Table 4 : Process of Immunofluorescence (IIF)
• Table 5 : Types of Agglutination Test
• Table 6 : Global Market for Autoimmune Disease Diagnostics, by Region, Through 2028
• Table 7 : North American Market for Autoimmune Disease Diagnostics, by Country, Through 2028
• Table 8 : European Market for Autoimmune Disease Diagnostics, by Country, Through 2028
• Table 9 : Asia-Pacific Market for Autoimmune Disease Diagnostics, by Country, Through 2028
• Table 10 : Rest of the World Market for Autoimmune Disease Diagnostics, by Country, Through 2028
• Table 11 : Global Market for Autoimmune Disease Diagnostics, by Gender, Through 2028
• Table 12 : North American Market for Autoimmune Disease Diagnostics, by Gender, Through 2028
• Table 13 : European Market for Autoimmune Disease Diagnostics, by Gender, Through 2028
• Table 14 : Asia-Pacific Market for Autoimmune Disease Diagnostics, by Gender, Through 2028
• Table 15 : Rest of the World Market for Autoimmune Disease Diagnostics, by Gender, Through 2028
• Table 16 : Global Market for Autoimmune Disease Diagnostics, by Indication, Through 2028
• Table 17 : Global Market for Autoimmune Disease Diagnostics for Type 1 Diabetes, by Region, Through 2028
• Table 18 : Global Market for Autoimmune Disease Diagnostics for Rheumatoid Arthritis, by Region, Through 2028
• Table 19 : Global Market for Autoimmune Disease Diagnostics for SLE, by Region, Through 2028
• Table 20 : Global Market for Autoimmune Disease Diagnostics for Psoriasis/Psoriatic Arthritis, by Region, Through 2028
• Table 21 : Global Market for Autoimmune Disease Diagnostics for Multiple Sclerosis, by Region, Through 2028
• Table 22 : Global Market for Autoimmune Disease Diagnostics for Inflammatory Bowel Disease, by Region, Through 2028
• Table 23 : Global Market for Autoimmune Disease Diagnostics for Other Disease Indications, by Region, Through 2028
• Table 24 : Global Market for Autoimmune Disease Diagnostics, by Technology, Through 2028
• Table 25 : Global Market for ELISA for Autoimmune Disease Diagnostics, by Region, Through 2028
• Table 26 : Global Market for Indirect Immunofluorescence (IIF) for Autoimmune Disease Diagnostics, by Region, Through 2028
• Table 27 : Global Market for Immunoblot for Autoimmune Disease Diagnostics, by Region, Through 2028
• Table 28 : Global Market for Multiplex Immunoassays for Autoimmune Disease Diagnostics, by Region, Through 2028
• Table 29 : Global Market for Other Technologies for Autoimmune Disease Diagnostics, by Region, Through 2028
• Table 30 : ESG Frameworks for the Global Autoimmune Disease Diagnostics Market
• Table 31 : Environmental (E) Factors in Autoimmune Disease Diagnostics
• Table 32 : Social Framework, Global Autoimmune Disease Diagnostics
• Table 33 : Social (S) Factors in Autoimmune Disease Diagnostics
• Table 34 : Governance (G) Factors in Autoimmune Disease Diagnostics
• Table 35 : Top Pharma Companies, ESG Ratings, 2022
• Table 36 : Sustainability at Roche, 2022
• Table 37 : Roche's Ten-Year Ambitions
• Table 38 : Global Autoimmune Disease Diagnostics Emerging Trends and Technologies
• Table 39 : Global Company Market Shares of Autoimmune Disease Diagnostics, 2022
• Table 40 : Patents on ELISA, 2018-Present
• Table 41 : Selected Manufacturer Patents on ELISA, 2018-Present
• Table 42 : Patents on Indirect Immunofluorescence, 2018-Present
• Table 43 : Selected Manufacturer Patents on Indirect Immunofluorescence, 2018-Present
• Table 44 : Patents on Western Blot, 2018-Present
• Table 45 : Selected Manufacturer Patents on Western Blot, 2018-Present
• Table 46 : Clinical Trials on Type 1 Diabetes Diagnostics, as of 2023
• Table 47 : Clinical Trials on Rheumatoid Arthritis Diagnostics, as of 2023
• Table 48 : Clinical Trials on Systemic Lupus Erythematosus Diagnostics, as of 2023
• Table 49 : Clinical Trials on Psoriasis Diagnostics, as of 2023
• Table 50 : Clinical Trials on Multiple Sclerosis Diagnostics, as of 2023
• Table 51 : Clinical Trials on Inflammatory Bowel Disease Diagnostics, as of 2023
• Table 52 : Global Autoimmune Disease Diagnostics Market: Mergers and Acquisitions, 2023
• Table 53 : Abbott: Product Information
• Table 54 : Abbott: Revenue, 2020-2022
• Table 55 : BD Biosciences: Product Information
• Table 56 : BD Biosciences: Revenue, 2020-2022
• Table 57 : Beckman Coulter Inc. (Danaher): Product Portfolio
• Table 58 : Danaher: Revenue, 2020-2022
• Table 59 : BioMerieux: Product Portfolio
• Table 60 : BioMerieux: Revenue, 2020-2022
• Table 61 : Bio-Rad: Product Portfolio
• Table 62 : Bio-Rad: Revenue, 2020-2022
• Table 63 : F. Hoffmann-La Roche AG: Product Portfolio
• Table 64 : F. Hoffmann-La Roche AG: Revenue, 2020-2022
• Table 65 : Quest Diagnostics: Revenue, 2020-2022
• Table 66 : Siemens Healthcare: Product Portfolio
• Table 67 : Siemens Healthcare: Revenue, 2020-2022
• Table 68 : Thermo Fisher Scientific: Product Portfolio
• Table 69 : Thermo Fisher Scientific: Revenue, 2020-2022
• Table 70 : Major Acronyms Used in This Report

List of Figures

• Summary Figure : Global Market Shares of Autoimmune Disease Diagnostics, by Technology Type, 2022
• Figure 1 : Enzyme-Linked Immunosorbent Assay (ELISA)
• Figure 2 : Indirect Immunofluorescence (IIF)
• Figure 3 : Western Blot (Immunoblot)
• Figure 4 : Rheumatoid Arthritis
• Figure 5 : SLE
• Figure 6 : Global Market Shares of Autoimmune Disease Diagnostics, by Region, 2022
• Figure 7 : North American Market Shares of Autoimmune Disease Diagnostics, by Country, 2022
• Figure 8 : European Market Shares of Autoimmune Disease Diagnostics, by Country, 2022
• Figure 9 : Asia-Pacific Market Shares of Autoimmune Disease Diagnostics, by Country, 2022
• Figure 10 : Global Market Shares of Autoimmune Disease Diagnostics, by Gender, 2022
• Figure 11 : North American Market Shares of Autoimmune Disease Diagnostics, by Gender, 2022
• Figure 12 : European Market Shares of Autoimmune Disease Diagnostics, by Gender, 2022
• Figure 13 : Asia-Pacific Market Shares of Autoimmune Disease Diagnostics, by Gender, 2022
• Figure 14 : Rest of the World Market Shares of Autoimmune Disease Diagnostics, by Gender, 2022
• Figure 15 : Global Market Shares of Autoimmune Disease Diagnostics, by Indication, 2022
• Figure 16 : Global Market Shares of Autoimmune Disease Diagnostics for Type 1 Diabetes, by Region, 2022
• Figure 17 : Global Market Shares of Autoimmune Disease Diagnostics for Rheumatoid Arthritis, by Region, 2022
• Figure 18 : Global Market Shares of Autoimmune Disease Diagnostics for SLE, by Region, 2022
• Figure 19 : Global Market Shares of Autoimmune Disease Diagnostics for Psoriasis/Psoriatic Arthritis, by Region, 2022
• Figure 20 : Global Market Shares of Autoimmune Disease Diagnostics for Multiple Sclerosis, by Region, 2022
• Figure 21 : Global Market Shares of Autoimmune Disease Diagnostics for Inflammatory Bowel Disease, by Region, 2022
• Figure 22 : Global Market Shares of Autoimmune Disease Diagnostics for Other Disease Indications, by Region, 2022
• Figure 23 : Global Market Shares of Autoimmune Disease Diagnostics, by Technology, 2022
• Figure 24 : Global Electricity Produced from Renewable Sources, 2017-2021
• Figure 25 : Global Recycled Waste, 2017-2021
• Figure 26 : Global CO₂ Emissions, 2017-2021
• Figure 27 : Global Company Market Shares of Autoimmune Disease Diagnostics, 2022